Regorafenib Improves Survival in Treatment-Refractory Colorectal Cancer
the Cancer Therapy Advisor take:
Compared with placebo, regorafenib improved overall survival in patients with treatment-refractory metastatic colorectal cancer, a recent study published online first in the journal The Lancet Oncology has shown.
For the double-blind, placebo-controlled, parallel-group, phase III trial, researchers enrolled 204 Asian patients with progressive metastatic colorectal cancer who had received at least two previous treatment lines or were unable to tolerate standard treatments. Participants were randomly assigned 2:1 to receive oral regorafenib 160mg once daily or placebo on days 1-21 of each 28-day cycle plus best supportive care.
Results showed that after a median follow-up of 7.4 months, median overall survival was 8.8 months (95% CI: 7.3-9.8) in the regorafenib group and 6.3 months (95% CI: 4.8-7.6) in the placebo group (HR = 0.55; 95% CI: 0.40-0.77; one-sided P = 0.00016).
In regard to safety, drug-related adverse events occurred in 97% of participants treated with regorafenib compared with 46% of those treated with placebo. The most common grade 3 or higher adverse events in the regorafenib group were hand-foot skin reaction, hypertension, hyperbilirubinemia, hypophosphatemia, elevated ALT/AST, elevated lipase concentration, and macropapular rash.
The findings suggest that regorafenib is an important treatment for patients with metastatic colorectal cancer whose disease has progressed after standard treatments, which may or may not include targeted treatments.
Compared with placebo, regorafenib improved overall survival in patients with treatment-refractory metastatic colorectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy
- Triclosan and Cancer Risk: Is There a Link?
- Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials
- Combined Modality Therapy May Be More Effective Than Radiotherapy Alone in Follicular Lymphoma
- Chemotherapy May Improve Survival Outcomes in High-Risk Soft-Tissue Sarcoma